About this item:

9 Views | 8 Downloads

Author Notes:

Correspondence: Alyssa Panitch, alyssa.panitch@bme.gatech.edu

Acknowledgements: The authors would like to thank Dr. Vanessa Franco Carvalho Dartora for her advice on the synthesis of the nanoparticles.

Author contributions: L.B.L. and A.P. contributed equally as co-senior authors. All authors have given approval to the final version of the manuscript.Julia Sapienza Passos: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing – Original draft, Writing – review & editing. Luciana Biagini Lopes: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing – Original draft, Writing – review & editing, Resources, Supervision, Funding acquisition. Alyssa Panitch: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing – Original draft, Writing – review & editing, Resources, Supervision, Project administration, Funding acquisition.

Competing interests: The authors declare no competing financial interest.

Subjects:

Research Funding:

This work was funded by FAPESP (grants #2021/12664-7, #2020/01208-8, and #2018/13877-1), CNPq (grant #306866/2020-0), and CAPES – Brazilian Federal Agency for Support and Evaluation of Graduate Education within the Ministry of Education of Brazil (finance code 001).

Keywords:

  • breast cancer
  • paclitaxel
  • lipid-polymeric nanoparticles
  • poly(N-isopropylacrylamide) (pNIPAM)
  • collagen binding peptide

Collagen-Binding Nanoparticles for Paclitaxel Encapsulation and Breast Cancer Treatment

Tools:

Journal Title:

ACS Biomaterials Science and Engineering

Volume:

Volume 9, Number 12

Publisher:

, Pages 6805-6820

Type of Work:

Article | Final Publisher PDF

Abstract:

In this study, we developed a novel hybrid collagen-binding nanocarrier for potential intraductal administration and local breast cancer treatment. The particles were formed by the encapsulation of nanostructured lipid carriers (NLCs) containing the cytotoxic drug paclitaxel within a shell of poly(N-isopropylacrylamide) (pNIPAM), and were functionalized with SILY, a peptide that binds to collagen type I (which is overexpressed in the mammary tumor microenvironment) to improve local retention and selectivity. The encapsulation of the NLCs in the pNIPAM shell increased nanoparticle size by approximately 140 nm, and after purification, a homogeneous system of hybrid nanoparticles (∼96%) was obtained. The nanoparticles exhibited high loading efficiency (<76%) and were capable of prolonging paclitaxel release for up to 120 h. SILY-modified nanoparticles showed the ability to bind to collagen-coated surfaces and naturally elaborated collagen. Hybrid nanoparticles presented cytotoxicity up to 3.7-fold higher than pNIPAM-only nanoparticles on mammary tumor cells cultured in monolayers. In spheroids, the increase in cytotoxicity was up to 1.8-fold. Compared to lipid nanoparticles, the hybrid nanoparticle modified with SILY increased the viability of nontumor breast cells by up to 1.59-fold in a coculture model, suggesting the effectiveness and safety of the system.

Copyright information:

© 2023 The Authors. Published by American Chemical Society

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote